#Japan #Tokyo #Mitsui Information #Lifebit Biotech #Biomedical Data

Mitsui Information Collaborates with Lifebit Biotech

Mitsui Information Co., Ltd., headquartered in Minato, Tokyo, has officially announced a strategic partnership with Lifebit Biotech Limited, a biotechnology company based in London, UK. This collaboration, formalized through a service partnership agreement, aims to introduce the Lifebit platform in Japan starting in July 2025. The initiative focuses on enhancing the secure utilization of intricate biomedical data, including genomic and clinical information, for biobanks, pharmaceutical companies, and healthcare organizations, supporting research and drug development efforts.

In recent years, the necessity for utilizing vast and diversified biomedical data in the medical and life sciences fields has surged. Researchers are under immense pressure to understand diseases better and increase the probability of successful drug discoveries. Particularly, the establishment of a secure analysis environment that respects personal data privacy while allowing the utilization of data across research institutions and borders is crucial for the advancement of next-generation medical research. However, existing technical and regulatory challenges have made achieving this a complex task.

To address these issues, Mitsui Information's agreement with Lifebit Biotech allows for a first-of-its-kind secure remote distributed analysis environment in Japan. This platform enables international collaborative research by ensuring data safety without necessitating the transfer of sensitive personal information. By utilizing this technology, Mitsui Information aims to promote collaborations with various domestic biobanks and pharmaceutical firms, establishing a standardized biomedical data analysis infrastructure that can be flexibly adapted to meet the unique needs of each organization. This collaborative effort is geared towards accelerating research and development in drug discovery and life sciences further.

Overview of the Lifebit Platform

1. Federated TRE (Trusted Research Environment): Built on patented TRE technology from Lifebit Biotech, this secure research analysis platform enables data analysis without transferring the data stored at participating institutions. It accommodates cross-border data analysis, catering to the interests of biobanks and pharmaceutical companies that wish to avoid moving data while still accessing large volumes of information. Users approved to use the platform can access, analyze, and store data from a single secure workspace with rigorous access controls ensuring data security.

2. TDL (Trusted Data Lakehouse™): This secure data integration platform allows for the harmonization of both structured and unstructured data within an organization into a common data model. It supports various data formats, including NGS data, PDF files, images, and electronic health records (EHR), ensuring versatility in data handling.

3. Target ID (Drug Discovery Support Tool): An AI-driven drug discovery assistance module provided by Lifebit Biotech, this tool leverages large-scale genomic and phenotypic data to significantly reduce drug target identification timelines, shortening them from 2-4 years to merely 2-6 weeks. It boasts a proven record of enhancing ROI by over 600% for prominent pharmaceutical companies.

Mitsui Information leverages its rich experience and robust IT integration capabilities to empower research and drug development in a diverse range of medical and research settings throughout Japan. Their commitment extends beyond platform implementation to ongoing operational support, user education, and technical assistance for international projects. Ultimately, they aim to build a globally recognized bio-data utilization model that delivers tangible value driven by local conditions and needs.

For further information, including product specifics, visit the Lifebit Biotech website here.

About Mitsui Information Co., Ltd.

Mitsui Information Co., Ltd. (MKI) operates under the purpose of “Connecting Knowledge to Create the Future.” With an ICT-centric business approach, MKI is committed to solving social challenges and creating new value alongside its customers, aspiring to realize its 2030 Vision of “Creating the Norms of Future Society.” The current mid-term management plan, initiated in April 2023, identifies this period as a phase of creativity and innovation, where MKI continually strives, as a value-creating company, to harness its decades of acquired knowledge and technology.

For inquiries about this product or service, please contact:

Mitsui Information Co., Ltd.
DX Sales Division, Bio Healthcare Sales Department
Email: Lifebit-Sales-dg@mki.co.jp